Related Experiment Video
Updated: Mar 3, 2026

Endoscopic Injection Sclerotherapy Assisted by Cyanoacrylate and Clips for Gastroesophageal Varices
Published on: June 13, 2025
Esophageal Crohn's Disease Successfully Treated With Risankizumab
Taylor Hallcox1, Daniel Stein1,2
1Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Esophageal Crohn's disease (CD) lacks specific treatments. This study suggests risankizumab, an interleukin-23 inhibitor, may be a promising option for managing this condition.
Area of Science:
- Gastroenterology
- Immunology
Background:
- Esophageal Crohn's disease (CD) is understudied but predicts intestinal CD progression.
- Current management relies on steroids, acid suppression, immunosuppressants, and anti-TNF agents, lacking specific guidelines.
- Interleukin-23 inhibitors, like risankizumab, show efficacy in CD remission.
More Related Videos
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...

